IN8bio says JCO publication shows INB-200 trial doubles progression-free survival in repeat-dose glioblastoma patients

IN8bio, Inc.

IN8bio, Inc.

INAB

0.00
  • IN8bio disclosed peer-reviewed Phase 1 data for INB-200 in newly diagnosed glioblastoma, published in the Journal of Clinical Oncology.
  • Repeat-dose patients posted median progression-free survival of 16.1 months, versus a ~6.9-month standard-of-care benchmark; no dose-limiting toxicities reported.
  • Across 13 treated patients, median progression-free survival was 9.9 months; median overall survival in repeat-dose patients was 19.5 months versus ~14.6 months historically.
  • Safety readout showed no cytokine release syndrome or ICANS in the study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607090800PRIMZONEFULLFEED9759336) on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.